Clinical Trial Update: Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial is evaluating almonertinib (HS-10296) for potentially resectable stage III EGFR-mutant non-small cell lung cancer. The study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (HS-10296) (almonertinib)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Non-small Cell Lung Cancer Stage III | Phase 2 | Status: ACTIVE_NOT_RECRUITING